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✦ Levalbuterol may be prescribed in place of racemic 
albuterol to help decrease the adverse effects thought to be 
mediated by the S-enantiomer in racemic albuterol.
✦ Racemic albuterol is a 50:50 mixture of R- and S-
enantiomers, whereas levalbuterol is only the R-
enantiomer.
✦ A review of literature shows conflicting results regarding 
levalbuterol adverse effects.
✦ There was a total of 15096 units of levalbuterol 0.625mg used 
in this time period which yielded an annual spending of $49816
✦ There was a total of 17214 units of levalbuterol 1.25mg used in 
this time period that yielded an annual spending of $68823.
✦ An interchange rate of 70% to 100% could yield a cost 
avoidance in the range of $71186 to $101695 annually.
✦ An annual drug usage evaluation for levalbuterol 0.625mg and 1.25mg was completed 
for the time period of January 1, 2012 through January 31, 2013 across all inpatient 
admissions for a 550 bed not-for-profit regional medical center.
✦ The consensus standard of interchange of racemic albuterol for levalbuterol occurs with 
a 2:1 ratio (e.g. racemic albuterol 2.5mg for levalbuterol 1.25mg and racemic albuterol 
1.25mg for levalbuterol 0.625mg).The cost avoidance for this study was calculated 
using this ratio.
✦ The annual cost avoidance of automatically interchanging racemic albuterol in place of 
levalbuterol was determined by comparing the purchase costs and usage of 
levalbuterol 0.625mg and 1.25mg against the purchase costs of racemic albuterol 
1.25mg and 2.5mg.
✦ The cost avoidance at interchange rates between 70% through 100% was calculated.
MATERIALS AND METHODS RESULTS BACKGROUND
PURPOSE
     The purpose of this retrospective drug usage evaluation was 
to determine if any cost avoidance would occur by utilizing 
an automatic therapeutic interchange of racemic albuterol for 
levalbuterol.
Northeast Georgia Interdisciplinary Team Members
Melissa Frank, Pharm.D, Clinical Coordinator, Pharmacy
Tracy Berry, RRT, Operations Manager, Respiratory Care
Anthony Alexander, RRT, Director, Respiratory Care
CONCLUSION
✦  Depending on the annual rate of conversion, the automatic 
therapeutic interchange of racemic albuterol in place of 
levalbuterol can yield an annual cost avoidance from $71186 
to $101695, 
✦  A protocol for automatic therapeutic interchange of racemic 
albuterol for levalbuterol can offer substantial savings, even 
at interchange rates of less than 100%.
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✦ Levalbuterol costs 3.5 to 25 times more than racemic 
albuterol.
✦ The range of cost avoidance using an automatic therapeutic 
interchange of racemic albuterol for levalbuterol can vary.
✦ Various health system pharmacies utilize different 
interchange rates
DISCUSSION
